New Zealand markets open in 55 minutes

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.2300-0.1000 (-7.52%)
At close: 04:00PM EDT
1.2200 -0.01 (-0.81%)
After hours: 04:34PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.3300
Open1.3000
Bid1.1800 x 4000
Ask1.2300 x 2200
Day's range1.1900 - 1.3249
52-week range1.1900 - 19.8700
Volume356,547
Avg. volume668,296
Market cap40.37M
Beta (5Y monthly)1.86
PE ratio (TTM)N/A
EPS (TTM)-3.2550
Earnings date03 Aug 2022 - 08 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.20
  • Zacks

    Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates

    Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -16.09% and 27.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update

    New Strategic Direction Focuses on Advancing the Clinical Stage Pipeline and Identifying Tebipenem’s Optimal Path to Value Creation Initiation of a Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial-Pulmonary Disease Expected in 2H 2022 SPR206’s Phase 1 Data Support Further Development in Complicated Urinary Tract Infection, Hospital-acquired and Ventilator-associated Bacterial Pneumonia, and Bloodstream Infections Conference Call and Live Webcast at 4:30 p.m. ET Today CAMBRIDGE, Mass., May

  • GlobeNewswire

    Spero Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 2022 RBC Capital Ma